5 Biotech Stocks to Buy Today According to Ken Fisher

Page 5 of 5

1. AstraZeneca PLC (NASDAQ:AZN)

Fisher Asset Management’s Stake Value: $908 million

Percentage of Fisher Asset Management’s 13F Portfolio: 0.5%

Number of Hedge Fund Holders: 42

AstraZeneca PLC (NASDAQ:AZN) is a biotechnology company that is involved in manufacturing pharmaceutical products. Its products target several diseases such as those of the lungs and kidneys, alongside psychiatric ailments.

By the end of the fourth quarter of last year, Fisher Investments held a $1.1 billion stake in AstraZeneca PLC (NASDAQ:AZN)  by owning 20 million shares. This made the investment firm the company’s largest investor. During the same time period, 42 out of the 924 hedge funds part of Insider Monkey’s survey had also invested in AstraZeneca PLC (NASDAQ:AZN).

For its fiscal fourth quarter, AstraZeneca PLC (NASDAQ:AZN) raked in $12 billion in revenue and $1.67 in non-GAAP EPS, beating analyst estimates for both. Stifel set a GBp 12,300 price target for the company in February 2022, sharing its belief that the firm’s growth rate is the strongest in the sector.

Disclosure: None. You can also take a look at 12 Best Large-cap Biotech Stocks To Buy Now and Billionaire Ken Fisher’s Top 10 High Dividend Stock Picks.

Page 5 of 5